At this point, all tumor cells are loaded with the new target antigen CD19, potentially extending the application of clinically approved anti-CD19 CAR-T cells to the treatment of solid tumors and overcoming the problem of target antigen expression heterogeneity. This evidence concerns the gene CD19 and neoplasm.